Literature DB >> 17975560

Course and complications of varicella zoster ophthalmicus in a high HIV seroprevalence population (Cape Town, South Africa).

J C Richards1, G Maartens, A J Davidse.   

Abstract

AIM: To describe the course and complications of varicella zoster ophthalmicus (VZO) in patients attending an eye clinic in a community with a high HIV seroprevalence. STUDY
DESIGN: Prospective cohort study of consecutive patients presenting to a tertiary hospital eye clinic with VZO.
METHOD: Patients recruited in 2001 and 2002 received standardized initial topical and systemic management, which was then modified according to complications. Information on the course and complications of the disease was entered in a database prior to statistical analysis.
RESULTS: Information on 102 patients who had 250 visits to the eye clinic was collected. HIV serology was positive, negative, and unknown in 66, 22, and 14 patients, respectively. The most common complication was uveitis (40/102). Median delay from onset of rash to starting acyclovir was 5 days. Complications were present in 33 patients at the first visit. Complications were commoner in patients with positive Hutchinson's sign and were less common at CD4 counts <200. At CD4 counts, > or =200 HIV infection had little effect on the course and complications of VZO. Timing of commencement of Acyclovir therapy within or after 72 h had no demonstrable effect on the incidence of new complications.
CONCLUSION: In a resource-limited setting, patients with the following characteristics should have immediate ophthalmic assessment: symptoms suggesting ocular complications or the presence of Hutchinson's sign. All VZO patients should receive antiviral therapy at the first doctor's visit even if they present >72 h after onset of the rash.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975560     DOI: 10.1038/sj.eye.6703027

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  1 in total

1.  Impact of Antiretroviral Therapy on the Risk of Herpes Zoster among Human Immunodeficiency Virus-Infected Individuals in Tanzania.

Authors:  Kosuke Kawai; Claudia A Hawkins; Ellen Hertzmark; Joel M Francis; David Sando; Aisa N Muya; Nzovu Ulenga; Wafaie W Fawzi
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.